Using 68Ga-grazytracer PET imaging to evaluate immunotherapy in lung cancer
The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer: a Prospective, Observationa Trial
Ruijin Hospital · NCT06623487
This study is testing if a special type of PET imaging can help doctors see how well immunotherapy is working for patients with stage III non-small cell lung cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Ruijin Hospital (other) |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT06623487 on ClinicalTrials.gov |
What this trial studies
This study focuses on patients with stage III non-small cell lung cancer (NSCLC) who are undergoing neoadjuvant immunotherapy. It aims to utilize 68Ga-grazytracer PET imaging to non-invasively detect the presence of CD8+ T cells in tumor lesions, which may provide insights into the treatment's efficacy. By monitoring these immune responses, the study seeks to enhance clinical decision-making regarding patient management and treatment strategies. The observational nature of the study allows for real-world data collection without altering patient treatment protocols.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-75 with stage III NSCLC who require neoadjuvant immunotherapy.
Not a fit: Patients with serious comorbidities or those who are pregnant or nursing may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved monitoring of immunotherapy effectiveness, potentially enhancing patient outcomes in NSCLC.
How similar studies have performed: While the use of PET imaging in cancer treatment monitoring is established, the specific application of 68Ga-grazytracer PET in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with stage III NSCLC, after assessment according to clinical guidelines, require neoadjuvant immunotherapy; 2. Fully-informed written consent obtained from patients; 3. Patient ability to comply with protocol requirements; 4. Age 18-75 years; 5. Life expectancy of at least 6 months. Exclusion Criteria: 1. Patients with serious diseases that the investigator deems unsuitable for participation in the clinical study. Such as severe cardiopulmonary insufficiency, severe bone marrow suppression, severe hepatic or renal insufficiency, etc; 2. Intestinal perforation, complete intestinal obstruction; 3. Patients with uncontrolled diabetes mellitus or a fasting blood glucose value of ≥11 mmol/L on the day of the test; 4. Pregnant women and women who are potentially pregnant, as well as nursing mothers; 5. Patients with poor compliance.
Where this trial is running
Shanghai, Shanghai Municipality
- Ruijin Hospital, Shanghai Jiao Tong University School of Medicine — Shanghai, Shanghai Municipality, China (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Carcinoma, Non-Small-Cell Lung, PET / CT, Neoadjuvant Immunotherapy